| Cipla Limited - Mumbai. Related news |
Cipla to acquire US specialty drugmaker Avenue Therapeutics for Rs 15.6 bn
Posted on 13th November 2018 |
.jpg) |
Cipla has entered into an agreement to acquire US-based specialty pharma company Avenue Therapeutics Inc for $215 mn or around Rs 15.6 bn. This is in line with Cipla's strategy of building a specialty drugs pipeline in the US. Cipla's US subsidiary InvaGen Pharmaceuticals Inc will make the acquisition in two stages, the company said. |
|
|
Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patients
Posted on 12th November 2018 |
.jpg) |
Drug major Cipla on Monday said it has received final approval from the US health regulator for Valganciclovir tablets used in the treatment of viral eye infection for AIDS patients. Valganciclovir is used in the treatment of cytomegalovirus infection (serious viral eye infection of the retina) for AIDS patients and for prevention of cytomegalovirus (CMV) disease after organ transplant. |
|
|
Cipla hits five-month low on weak outlook; down 12% in two days
Posted on 6th November 2018 |
.jpg) |
Shares of Cipla hit a five-month low of Rs 534, down 5% on Tuesday, extending its Monday’s 7% decline on the BSE, due to the weak outlook for the second half of the current fiscal (H2FY19). The pharmaceuticalmajor said there was pressure on the tender business, supply disruptions, commodity inflation and business impact from countries hit by sanctions. |
|
|
Cipla records sharpest fall in one year post Q2 results; stock down 8%
Posted on 5th November 2018 |
.jpg) |
Shares of Cipla dipped 8% to Rs 558 on the BSE after the pharmaceutical company posted an 11% decline in its consolidated net profit at Rs 3.77 billion for the September quarter (Q2FY19). It had reported a profit of Rs 4.23 billion in the year-ago quarter. The stock recorded its sharpest intra-day fall in since November 7, 2017. |
|
|
Cipla nears its 52-week high post Q1 results
Posted on 9th August 2018 |
.jpg) |
Shares of Cipla have rallied 4.6% to Rs 662 per share on the BSE in early morning trade after the pharmaceutical company reported a 10% increase in its consolidated net profit of Rs 4.51 billion for the first quarter ended June 30 (Q1FY19), driven by healthy growth in domestic market. It had profit of Rs 4.09 billion in the same quarter year ago. The stock was trading close to its 52-week high of Rs 663 touched on November 11, 2017 on the BSE in intra-day trade. It hit an all-time high of Rs 752 on March 10, 2015. |
|
|
Cipla acquires 100% stake in South African pharmaceutical company Mirren
Posted on 12th July 2018 |
.jpg) |
Cipla has acquired a 100 per cent stake in Mirren, a South African over-the-counter (OTC) pharmaceutical manufacturer and distributor. The transaction is subject to the approval by the Competition Commission of South Africa. Paul Miller, CEO of Cipla South Africa, said that once approved, the transaction will enhance Cipla's current OTC portfolio, by adding Mirren's well-established brands like Bronco! |
|
|
Pricing woes force Cipla, Glenmark, Lupin to go slow on US drug pipeline
Posted on 27th February 2018 |
.jpg) |
Faced with pricing pressure, large Indian pharmaceutical companies are focusing on selective product launches in the US market. The move comes amid increasing competition in the generic drug space and customer consolidation, which are impacting the companies' profits. “I do not think we are going to file more than 20 products in a year, but we will choose them well. Nowadays, in the US, you think you have a very good product but there are eight companies filing the product on day one and then there another five after that. |
|
|
|
|
|
|
|
|
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
